In the evolving field of peptide chemistry, few compounds have garnered as much interest as AXT107 peptide. As someone who follows the latest advancements in synthetic biology and biomimetic research, I have spent considerable time analyzing the structural and functional properties of this unique molecule. Often referred to by its generic name, Gersizangitide, this compound represents a fascinating intersection of structural biology and vascular stabilization research.
Understanding the Structural Mechanism of AXT107
At its core, AXT107 is a collagen IV-derived peptide consisting of 20 amino acids. Gersizangitide (also known asAXT 107) is an angiogenesis inhibitor, being developed by AsclepiX Therapeutics, for the treatment of diabetic macular oedema, Unlike standard signaling molecules, this synthetic peptide is designed to function as a mimetic, specifically engineered to interact with complex biological pathways.
The primary mechanism that makes AXT107 stand out is its ability to bind to integrins, specifically αvβ3 and α5β1, with exceptionally high affinity. By binding to these integrins, the peptide effectively disrupts the VEGFR2-β3 complex. This is a crucial distinction from traditional inhibitors, as it allows the molecule to exert control over vascular signaling pathways—specifically by blocking pro-angiogenic VEGF signals while simultaneously promoting vascular stabilization through Tie2 activation.
Why AXT107 Peptide is a Subject of Intense Scientific Study
From a researcher’s perspective, the interest in this compound stems from its multi-pathway interference. While many conventional agents target only VEGF, AXT107 interferes with three distinct signaling pathways that underlie blood vessel growth: VEGFR2, c-Met, and PDGFRβ.
This "one-two punch" approach is what researchers describe when discussing how i gersizangitide (AXT107) / Asclepix t stops abnormal blood vessels in the eye from leaking vision-blocking fluids. By resolving TNFα-induced vascular inflammation in endothelial cells, the peptide acts as a regulator, converting endogenously released Ang2 into an agonist of Tie2 signaling. This dual-action mechanism is why it is often categorized as a "Gel Forming Peptide," providing a sustained release profile that is highly desirable in long-term observational studies.
Key Observations and Data Points
Based on the available documentation, here are the technical specifications that define this molecule:
* Classification: Collagen IV-derived, anti-angiogenic peptide.
* Molecular Target: Integrins αvβ3 and α5β1 (Kd=1.29 and 2.21 nM).
* Primary Function: Inhibits VEGFR2 signaling and activates Tie2.
* Clinical Potential: Investigational studies have explored AXT107 0.1 mg/eye as a potential dosage for evaluating biological activity.
Furthermore, the data suggests that AXT107 is safe for intr May 6, 2024—AsclepiX's lead clinical candidate,integrin regulating peptide AXT107, has a novel mechanism of action that inhibits neovascularization Read more avitreal injection, with some studies indicating that its structural stability could support potentially once-a-year dosing in clinical settings. This longevity is a significant improvement over existing therapies that require much more frequent administration.
Personal Perspective on Pepti Stable Gastric Pentadecapeptide BPC 157—Possible Novel Therapy of de Research
My interest in AXT107, a collagen-derived peptide, is purely academic. In the world of peptide research, it is vital to distinguish between commercial supplements and advanced investigational drug candidates like AXT-107. Because it is a highly specialized molecule, it is not a "lifestyle" peptide but rather a sophisticated tool for Gersizangitide (AXT-107) | Angiogenesis Inhibitor understanding vascular physiology.
When review Suppression of Ocular Vascular Inflammation through ing the literature on AXT107, a collagen IV-derived peptide, one cannot help but be impressed by the precision of its design. By targeting the root causes of vascular leakage—rather than just the symptoms—this integrin regulating peptide AXT107 sets a First patient dosed in AXT107 clinical trial for DME high bar for Synthetic Peptide May Curb Macular Degeneration-Based future synthetic biology.
Final Thoughts
Whether you are following the progress of AsclepiX Therapeutics or simply interested in how AXT107 inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2), it is clear that this molecule is at the forefront of modern biochemistry. The ability of AXT107 to restore healthy, non-leaky vasculature is a testament to the power of mimicking natural collagen structures to solve complex biological challenges. As research continues to advance, the role of this tyrosine kinase blocking collagen IV-derived peptide will undoubtedly remain a cornerstone of vascular stabilization studies.
*Disclaimer: This article is for informational purposes based on publicly available research and does not constitute medical advice or recommendations for human use.*